{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:37:28Z","timestamp":1790753848074,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chemoresistance remains the primary challenge of clinical treatment of gastric cancer (GC), making the biomarkers of chemoresistance crucial for treatment decision. Our previous study has reported that p21-actived kinase 6 (PAK6) is a prognostic factor for selecting which patients with GC are resistant to 5-fluorouracil\/oxaliplatin chemotherapy. However, the mechanistic role of PAK6 in chemosensitivity remains unknown. The present study identified PAK6 as an important modulator of the DNA damage response (DDR) and chemosensitivity in GC. Analysis of specimens from patients revealed significant associations between the expression of PAK6 and poorer stages, deeper invasion, more lymph node metastases, higher recurrence rates, and resistance to oxaliplatin. Cells exhibited chemosensitivity to oxaliplatin after knockdown of PAK6, but showed more resistant to oxaliplatin when overexpressing PAK6. Functionally, PAK6 mediates cancer chemoresistance by enhancing homologous recombination (HR) to facilitate the DNA double-strand break repair. Mechanistically, PAK6 moves into nucleus to promote the activation of ATR, thereby further activating downstream repair protein CHK1 and recruiting RAD51 from cytoplasm to the DNA damaged site to repair the broken DNA in GC. Activation of ATR is the necessary step for PAK6 mediated HR repair to protect GC cells from oxaliplatin-induced apoptosis, and ATR inhibitor (AZD6738) could block the PAK6-mediated HR repair, thereby reversing the resistance to oxaliplatin and even promoting the sensitivity to oxaliplatin regardless of high expression of PAK6. In conclusion, these findings indicate a novel regulatory mechanism of PAK6 in modulating the DDR and chemoresistance in GC and provide a reversal suggestion in clinical decision.<\/jats:p>","DOI":"10.1038\/s41419-022-05118-8","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T18:16:03Z","timestamp":1659032163000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["PAK6 promotes homologous-recombination to enhance chemoresistance to oxaliplatin through ATR\/CHK1 signaling in gastric cancer"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8046-1151","authenticated-orcid":false,"given":"Weicai","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zepang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5443-2886","authenticated-orcid":false,"given":"Shitong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2773-7048","authenticated-orcid":false,"given":"Guoxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"5118_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NCT, Lordick F. Gastric cancer. Lancet. 2020;396:635\u201348.","journal-title":"Lancet"},{"key":"5118_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"5118_CR3","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cgh.2019.07.045","volume":"18","author":"AP Thrift","year":"2020","unstructured":"Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol. 2020;18:534\u201342.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5118_CR4","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","volume":"26","author":"S-E Al-Batran","year":"2008","unstructured":"Al-Batran S-E, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435\u201342.","journal-title":"J Clin Oncol"},{"key":"5118_CR5","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1023\/A:1008213732429","volume":"9","author":"E Raymond","year":"1998","unstructured":"Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9:1053\u201371.","journal-title":"Ann Oncol"},{"key":"5118_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/cam4.1274","volume":"7","author":"N Charalampakis","year":"2018","unstructured":"Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, et al. Medical management of gastric cancer: a 2017 update. Cancer Med. 2018;7:123\u201333.","journal-title":"Cancer Med"},{"key":"5118_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.semcancer.2018.01.006","volume":"54","author":"CK Rane","year":"2019","unstructured":"Rane CK, Minden A. P21 activated kinase signaling in cancer. Semin Cancer Biol. 2019;54:40\u201349.","journal-title":"Semin Cancer Biol"},{"key":"5118_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrc3645","volume":"14","author":"M Radu","year":"2014","unstructured":"Radu M, Semenova G, Kosoff R, Chernoff J. PAK signalling during the development and progression of cancer. Nat Rev Cancer. 2014;14:13\u201325.","journal-title":"Nat Rev Cancer"},{"key":"5118_CR9","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/mc.22611","volume":"56","author":"M Babagana","year":"2017","unstructured":"Babagana M, Johnson S, Slabodkin H, Bshara W, Morrison C, Kandel ES. P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells. Mol Carcinog. 2017;56:1515\u201325.","journal-title":"Mol Carcinog"},{"key":"5118_CR10","doi-asserted-by":"publisher","first-page":"118888","DOI":"10.1016\/j.bbamcr.2020.118888","volume":"1868","author":"J Zheng","year":"2021","unstructured":"Zheng J, Zhang C, Li Y, Jiang Y, Xing B, Du X. p21-activated kinase 6 controls mitosis and hepatocellular carcinoma progression by regulating Eg5. Biochim Biophys Acta Mol Cell Res. 2021;1868:118888.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"5118_CR11","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.7150\/thno.42874","volume":"10","author":"T Li","year":"2020","unstructured":"Li T, Li Y, Liu T, Hu B, Li J, Liu C, et al. Mitochondrial PAK6 inhibits prostate cancer cell apoptosis via the PAK6-SIRT4-ANT2 complex. Theranostics. 2020;10:2571\u201386.","journal-title":"Theranostics"},{"key":"5118_CR12","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1182\/blood.2019003636","volume":"136","author":"H Lin","year":"2020","unstructured":"Lin H, Rothe K, Chen M, Wu A, Babaian A, Yen R, et al. The miR-185\/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML. Blood. 2020;136:596\u2013609.","journal-title":"Blood"},{"key":"5118_CR13","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.urology.2008.09.041","volume":"73","author":"X Wen","year":"2009","unstructured":"Wen X, Li X, Liao B, Liu Y, Wu J, Yuan X, et al. Knockdown of p21-activated Kinase 6 Inhibits Prostate Cancer Growth and Enhances Chemosensitivity to Docetaxel. Urology. 2009;73:1407\u201311.","journal-title":"Urology"},{"key":"5118_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ebiom.2017.06.028","volume":"22","author":"Y Jiang","year":"2017","unstructured":"Jiang Y, Liu W, Li T, Hu Y, Chen S, Xi S, et al. Prognostic and Predictive Value of p21-activated Kinase 6 Associated Support Vector Machine Classifier in Gastric Cancer Treated by 5-fluorouracil\/Oxaliplatin Chemotherapy. EBioMedicine. 2017;22:78\u201388.","journal-title":"EBioMedicine"},{"key":"5118_CR15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1101\/gad.294082.116","volume":"31","author":"A Vancevska","year":"2017","unstructured":"Vancevska A, Douglass KM, Pfeiffer V, Manley S, Lingner J. The telomeric DNA damage response occurs in the absence of chromatin decompaction. Genes Dev. 2017;31:567\u201377.","journal-title":"Genes Dev"},{"key":"5118_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.molcel.2011.03.019","volume":"42","author":"A Bothmer","year":"2011","unstructured":"Bothmer A, Robbiani DF, Di Virgilio M, Bunting SF, Klein IA, Feldhahn N, et al. Regulation of DNA end joining, resection, and immunoglobulin class switch recombination by 53BP1. Mol Cell. 2011;42:319\u201329.","journal-title":"Mol Cell"},{"key":"5118_CR17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature24060","volume":"550","author":"W Zhao","year":"2017","unstructured":"Zhao W, Steinfeld JB, Liang F, Chen X, Maranon DG, Jian Ma C, et al. BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing. Nature. 2017;550:360\u20135.","journal-title":"Nature"},{"key":"5118_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.semcancer.2019.02.005","volume":"58","author":"A Motegi","year":"2019","unstructured":"Motegi A, Masutani M, Yoshioka K-I, Bessho T. Aberrations in DNA repair pathways in cancer and therapeutic significances. Semin Cancer Biol. 2019;58:29\u201346.","journal-title":"Semin Cancer Biol"},{"key":"5118_CR19","doi-asserted-by":"publisher","first-page":"107450","DOI":"10.1016\/j.pharmthera.2019.107450","volume":"207","author":"A Bradbury","year":"2020","unstructured":"Bradbury A, Hall S, Curtin N, Drew Y. Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations? Pharm Ther. 2020;207:107450.","journal-title":"Pharm Ther"},{"key":"5118_CR20","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.molcel.2019.05.036","volume":"75","author":"C Colomer","year":"2019","unstructured":"Colomer C, Margalef P, Villanueva A, Vert A, Pecharroman I, Sol\u00e9 L, et al. IKK\u03b1 kinase regulates the DNA damage response and drives chemo-resistance in cancer. Mol Cell. 2019;75:669\u201382.","journal-title":"Mol Cell"},{"key":"5118_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.35772\/ghm.2020.01075","volume":"3","author":"S Yagi","year":"2021","unstructured":"Yagi S, Yamada K, Terayama M, Wake H, Enomoto N, Nohara K, et al. Current status of doublet combinations of platinum and fluoropyrimidines using oxaliplatin for advanced gastric cancer. Glob Health Med. 2021;3:31\u201336.","journal-title":"Glob Health Med"},{"key":"5118_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36\u201346.","journal-title":"N Engl J Med"},{"key":"5118_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0006-2952(03)00260-0","volume":"66","author":"S Faivre","year":"2003","unstructured":"Faivre S, Chan D, Salinas R, Woynarowska B, Woynarowski JM. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharm. 2003;66:225\u201337.","journal-title":"Biochem Pharm"},{"key":"5118_CR24","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1158\/0008-5472.CAN-07-3063","volume":"68","author":"K Yamauchi","year":"2008","unstructured":"Yamauchi K, Yang M, Hayashi K, Jiang P, Yamamoto N, Tsuchiya H, et al. Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy. Cancer Res. 2008;68:516\u201320.","journal-title":"Cancer Res"},{"key":"5118_CR25","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/bcp.13155","volume":"83","author":"F Hammann","year":"2017","unstructured":"Hammann F, Gotta V, Conen K, Medinger M, Cesana P, Rochlitz C, et al. Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity. Br J Clin Pharm. 2017;83:927\u201330.","journal-title":"Br J Clin Pharm"},{"key":"5118_CR26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.18632\/oncotarget.2803","volume":"6","author":"J Chen","year":"2015","unstructured":"Chen J, Lu H, Yan D, Cui F, Wang X, Yu F, et al. PAK6 increase chemoresistance and is a prognostic marker for stage II and III colon cancer patients undergoing 5-FU based chemotherapy. Oncotarget. 2015;6:355\u201367.","journal-title":"Oncotarget"},{"key":"5118_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jss.2014.01.049","volume":"189","author":"H Chen","year":"2014","unstructured":"Chen H, Miao J, Li H, Wang C, Li J, Zhu Y, et al. Expression and prognostic significance of p21-activated kinase 6 in hepatocellular carcinoma. J Surg Res. 2014;189:81\u201388.","journal-title":"J Surg Res"},{"key":"5118_CR28","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.3892\/ol.2020.11797","volume":"20","author":"Q Yang","year":"2020","unstructured":"Yang Q, Zhao Y, Chen Y, Chang Y, Huang A, Xu T, et al. PAK6 promotes cervical cancer progression through activation of the Wnt\/\u03b2-catenin signaling pathway. Oncol Lett. 2020;20:2387\u201395.","journal-title":"Oncol Lett"},{"key":"5118_CR29","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/pros.21114","volume":"70","author":"M Zhang","year":"2010","unstructured":"Zhang M, Siedow M, Saia G, Chakravarti A. Inhibition of p21-activated kinase 6 (PAK6) increases radiosensitivity of prostate cancer cells. Prostate. 2010;70:807\u201316.","journal-title":"Prostate"},{"key":"5118_CR30","doi-asserted-by":"publisher","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","volume":"61","author":"KM Foote","year":"2018","unstructured":"Foote KM, Nissink JWM, McGuire T, Turner P, Guichard S, Yates JWT, et al. Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent. J Med Chem. 2018;61:9889\u2013907.","journal-title":"J Med Chem"},{"key":"5118_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","volume":"7","author":"JS Brown","year":"2017","unstructured":"Brown JS, Carrigan B, Jackson SP, Yap TA. Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discov. 2017;7:20.","journal-title":"Cancer Discov"},{"key":"5118_CR32","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1136\/gutjnl-2019-319984","volume":"70","author":"L Perkhofer","year":"2021","unstructured":"Perkhofer L, Gout J, Roger E, Kude de Almeida F, Baptista Simoes C, Wiesmuller L, et al. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Gut. 2021;70:606\u201317.","journal-title":"Gut"},{"key":"5118_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ncb1212","volume":"7","author":"CS S\u00f8rensen","year":"2005","unstructured":"S\u00f8rensen CS, Hansen LT, Dziegielewski J, Sylju\u00e5sen RG, Lundin C, Bartek J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol. 2005;7:195\u2013201.","journal-title":"Nat Cell Biol"},{"key":"5118_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00018-019-03365-1","volume":"77","author":"Y Sun","year":"2020","unstructured":"Sun Y, McCorvie TJ, Yates LA, Zhang X. Structural basis of homologous recombination. Cell Mol life Sci: CMLS. 2020;77:3\u201318.","journal-title":"Cell Mol life Sci: CMLS"},{"key":"5118_CR35","doi-asserted-by":"publisher","first-page":"107492","DOI":"10.1016\/j.pharmthera.2020.107492","volume":"208","author":"E Laurini","year":"2020","unstructured":"Laurini E, Marson D, Fermeglia A, Aulic S, Fermeglia M, Pricl S. Role of Rad51 and DNA repair in cancer: a molecular perspective. Pharm Ther. 2020;208:107492.","journal-title":"Pharm Ther"},{"key":"5118_CR36","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1139\/bcb-2016-0012","volume":"94","author":"SK Godin","year":"2016","unstructured":"Godin SK, Sullivan MR, Bernstein KA. Novel insights into RAD51 activity and regulation during homologous recombination and DNA replication. Biochem Cell Biol. 2016;94:407\u201318.","journal-title":"Biochem Cell Biol"},{"key":"5118_CR37","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1093\/nar\/gks270","volume":"40","author":"L Krejci","year":"2012","unstructured":"Krejci L, Altmannova V, Spirek M, Zhao X. Homologous recombination and its regulation. Nucleic Acids Res. 2012;40:5795\u2013818.","journal-title":"Nucleic Acids Res"},{"key":"5118_CR38","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1074\/jbc.M406701200","volume":"280","author":"R Kaur","year":"2005","unstructured":"Kaur R, Liu X, Gjoerup O, Zhang A, Yuan X, Balk SP, et al. Activation of p21-activated Kinase 6 by MAP Kinase Kinase 6 and p38 MAP Kinase *. J Biol Chem. 2005;280:3323\u201330.","journal-title":"J Biol Chem"},{"key":"5118_CR39","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/SLA.0000000000002116","volume":"267","author":"Y Jiang","year":"2018","unstructured":"Jiang Y, Zhang Q, Hu Y, Li T, Yu J, Zhao L, et al. ImmunoScore signature: a prognostic and predictive tool in gastric cancer. Ann Surg. 2018;267:504\u201313.","journal-title":"Ann Surg"},{"key":"5118_CR40","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","volume":"39","author":"RL Lloyd","year":"2020","unstructured":"Lloyd RL, Wijnhoven PWG, Ramos-Montoya A, Wilson Z, Illuzzi G, Falenta K, et al. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene. 2020;39:4869\u201383.","journal-title":"Oncogene"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05118-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05118-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05118-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T15:09:33Z","timestamp":1669302573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05118-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["5118"],"URL":"https:\/\/doi.org\/10.1038\/s41419-022-05118-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"30 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Southern Medical University Nanfang Hospital. Informed consent was not obtained in the study in view of the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"658"}}